Renaissance Technologies LLC Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL

Renaissance Technologies LLC reduced its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 32.8% during the first quarter, HoldingsChannel reports. The firm owned 1,938,145 shares of the company’s stock after selling 945,600 shares during the period. Renaissance Technologies LLC’s holdings in Zentalis Pharmaceuticals were worth $4,535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Sei Investments Co. increased its holdings in Zentalis Pharmaceuticals by 14.6% in the 1st quarter. Sei Investments Co. now owns 191,551 shares of the company’s stock worth $448,000 after buying an additional 24,451 shares in the last quarter. State of Wyoming bought a new position in Zentalis Pharmaceuticals during the 1st quarter valued at about $67,000. Dimensional Fund Advisors LP boosted its holdings in shares of Zentalis Pharmaceuticals by 182.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock valued at $634,000 after acquiring an additional 175,771 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Zentalis Pharmaceuticals in the first quarter worth approximately $74,000. Finally, Invesco Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 8.6% during the fourth quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after purchasing an additional 14,961 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ZNTL. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an “outperform” rating and a $8.00 target price for the company. Guggenheim increased their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.75.

Zentalis Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:ZNTL opened at $5.00 on Friday. The firm’s 50 day moving average price is $4.31 and its 200-day moving average price is $3.59. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.21 and a twelve month high of $6.95. The stock has a market capitalization of $355.95 million, a PE ratio of -2.89 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Analysts expect that Zentalis Pharmaceuticals, Inc. will post -1.83 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.